Free Trial

Supernus Pharmaceuticals (SUPN) Competitors

Supernus Pharmaceuticals logo
$50.17 +0.41 (+0.82%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$50.83 +0.66 (+1.31%)
As of 10/17/2025 05:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SUPN vs. CORT, JAZZ, PRGO, NKTR, PCRX, OMER, ASMB, CPIX, LLY, and JNJ

Should you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry.

Supernus Pharmaceuticals vs. Its Competitors

Corcept Therapeutics (NASDAQ:CORT) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

93.6% of Corcept Therapeutics shares are owned by institutional investors. 20.8% of Corcept Therapeutics shares are owned by insiders. Comparatively, 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Corcept Therapeutics has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$675.04M12.28$141.21M$1.1369.64
Supernus Pharmaceuticals$661.82M4.25$73.86M$1.1543.63

Corcept Therapeutics currently has a consensus price target of $135.25, suggesting a potential upside of 71.88%. Supernus Pharmaceuticals has a consensus price target of $64.00, suggesting a potential upside of 27.57%. Given Corcept Therapeutics' higher probable upside, analysts plainly believe Corcept Therapeutics is more favorable than Supernus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corcept Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Supernus Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00

Corcept Therapeutics has a net margin of 18.51% compared to Supernus Pharmaceuticals' net margin of 9.70%. Corcept Therapeutics' return on equity of 20.10% beat Supernus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Corcept Therapeutics18.51% 20.10% 16.20%
Supernus Pharmaceuticals 9.70%14.22%10.82%

Corcept Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Supernus Pharmaceuticals has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.

In the previous week, Corcept Therapeutics had 16 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 19 mentions for Corcept Therapeutics and 3 mentions for Supernus Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.81 beat Supernus Pharmaceuticals' score of 0.46 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corcept Therapeutics
9 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Supernus Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Corcept Therapeutics beats Supernus Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

Get Supernus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SUPN vs. The Competition

MetricSupernus PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.79B$4.47B$6.09B$10.49B
Dividend YieldN/A0.89%5.73%4.80%
P/E Ratio43.6310.8585.3027.13
Price / Sales4.2521.46519.71179.96
Price / Cash11.937.0637.2361.22
Price / Book2.674.2712.236.52
Net Income$73.86M-$134.23M$3.33B$276.93M
7 Day Performance2.39%1.74%1.18%1.93%
1 Month Performance8.76%14.77%6.15%2.19%
1 Year Performance45.25%64.40%60.00%34.99%

Supernus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SUPN
Supernus Pharmaceuticals
4.0612 of 5 stars
$50.17
+0.8%
$64.00
+27.6%
+48.3%$2.79B$661.82M43.63580
CORT
Corcept Therapeutics
4.9093 of 5 stars
$89.85
+1.9%
$135.25
+50.5%
+66.8%$9.29B$716.08M79.51300Analyst Downgrade
Insider Trade
JAZZ
Jazz Pharmaceuticals
4.5705 of 5 stars
$137.58
-1.4%
$178.93
+30.1%
+18.7%$8.46B$4.07B-20.442,800
PRGO
Perrigo
4.849 of 5 stars
$22.07
-2.0%
$34.00
+54.1%
-13.3%$3.10B$4.37B-38.058,379News Coverage
Positive News
Analyst Downgrade
NKTR
Nektar Therapeutics
4.0364 of 5 stars
$59.93
-1.0%
$91.67
+53.0%
+165.6%$1.15B$98.43M-6.81220
PCRX
Pacira BioSciences
4.2489 of 5 stars
$23.87
-3.9%
$33.40
+39.9%
+34.9%$1.12B$705.85M-8.59720News Coverage
Positive News
OMER
Omeros
4.311 of 5 stars
$4.61
+0.7%
$18.00
+290.5%
+95.7%$311.70MN/A-2.18210Trending News
Analyst Forecast
Analyst Revision
Gap Down
ASMB
Assembly Biosciences
3.5235 of 5 stars
$24.48
+5.0%
$41.25
+68.5%
+62.7%$178.92M$28.52M-4.39100Analyst Forecast
CPIX
Cumberland Pharmaceuticals
0.6259 of 5 stars
$3.09
-1.3%
N/A+168.8%$46.83M$37.87M-14.0580
LLY
Eli Lilly and Company
4.9759 of 5 stars
$845.40
+0.7%
$938.94
+11.1%
-12.4%$794.90B$45.04B55.2547,000Trending News
Analyst Upgrade
Gap Down
JNJ
Johnson & Johnson
4.8434 of 5 stars
$188.23
-0.2%
$189.12
+0.5%
+17.5%$454.31B$88.82B20.13138,100Trending News
Earnings Report
Dividend Announcement
Analyst Forecast
Analyst Revision

Related Companies and Tools


This page (NASDAQ:SUPN) was last updated on 10/18/2025 by MarketBeat.com Staff
From Our Partners